Search
Back

Icatibant Acetate

CAS 138614-30-9
Icatibant Acetate

General Information

Icatibant acetate is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults. HAE is a rare, potentially life-threatening disease characterized by intermittent and unpredictable attacks of sudden swelling involving various organs.


About the API

Therapeutic category Blood and Blood Forming Organs
Available formulations Injectables
Regulations
  • Japan DMF
  • Korea DMF
  • US DMF

Updates About Icatibant Acetate

June 27, 2016
New US DMF for Icatibant Acetate dated 6/2016 is available.
February 2, 2020
New Canada DMF for Icatibant Acetate is available.

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.